Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or New Mexico for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to New Mexico only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. New Mexico (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Jacqueline Dean (NPI 1184690364)

Field	Value
Entity Type	Individual
Organization	Jacqueline Dean
Address	1617 University Blvd Ne
City	Albuquerque
State	NM
ZIP	87102
Taxonomy	Rheumatology Physician
NPI Enumerated	February 27, 2006

Payer Source	Total Paid
Medicare	$601.6K
Medicaid	$0

Key Findings

This provider is a rheumatology-focused outpatient infusion practice by code mix and revenue concentration: the top drug code J0129 (abatacept) accounts for $353.7K in Medicare revenue (58.9% of the provider's total Medicare revenue) and the provider reports 10.4K claims for that code, indicating heavy reliance on physician-administered biologic therapy rather than clinic-only evaluation and management visits. Additional high-revenue biologic codes reported (J1602, J0897, J1745) reinforce that the operation centers on infusion/IV or supervised injectable biologic administration rather than procedure-based specialties.

Revenue concentration is high: the precomputed top-3 Medicare codes by revenue together account for 78.3% of this provider's total Medicare revenue, creating a narrow revenue base dominated by a few biologic drug codes. That concentration implies operational and payer-negotiation sensitivity to changes in biologic utilization, reimbursement, or interchange with biosimilars.

Scale and payer mix are effectively single-payer for federal programs: total Medicare revenue is $601.6K while there is no Medicaid billing on file, meaning Medicaid contributes $0 to the dataset and the provider’s publicly visible government-revenue footprint is essentially Medicare-only. This profile indicates limited exposure to Medicaid patient volume and state-program reimbursement dynamics in the available claims.

Competitive standing on the largest revenue code is middle-of-the-pack nationally: J0129 ranks #457 of 1221 providers nationally (63th percentile; typical, unremarkable volume for this code), so the provider is a meaningful but not dominant national participant in abatacept administration. Other high-revenue drugs show mixed national positions — J1602 at #900 of 1041 (14th percentile; typical, unremarkable volume) and J0897 at #4342 of 10057 (56th percentile; typical, unremarkable volume) — indicating variable competitiveness across specific biologics.

Ambulatory E/M activity is present but small relative to drug revenue: 99213 generated $23.9K (4.0% of Medicare revenue) across 398 claims and ranks #39333 of 457151 providers nationally (91th percentile; typical, unremarkable volume for this code), suggesting steady established-patient clinic visits that support the infusion workload but do not drive overall revenue. In contrast, infusion- and chemotherapy-administration codes such as 96413 ($12.3K, 137 claims), 96365 ($7.9K, 171 claims), and 96415 ($2.8K, 138 claims) confirm an on-site infusion capability.

Several revenue-driving codes are at or near median national activity, which supports characterization as a typical local infusion provider rather than a regional or national center of excellence: J0897 is at the 56th percentile (typical, unremarkable volume), J1745 is at the 26th percentile (typical, unremarkable volume), and 99214 sits at the 54th percentile (typical, unremarkable volume). These positions imply routine clinical volumes without extreme outlier behavior.

There is measurable variation in national standing across specific biologics that could affect contracting strategy: J1602 shows low national standing (#900 of 1041; 14th percentile; typical, unremarkable volume) and J0717 reports very low percentile placement (#836 of 848; 1th percentile; typical, unremarkable volume), signaling that for some therapies this provider is a modest participant nationally and might be less influential in supply or reimbursement negotiations for those agents.

Tenure is long enough to reflect an established practice: the NPI was enumerated 2006-02-27 (~20 years ago), indicating sustained presence in the Medicare program and a billing history that supports longitudinal review for utilization patterns and changes in biologic mix over time.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

15 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	10,400	$30	$353.7K
J1602	Injection, golimumab, 1 mg, for intravenous use	5,990	$10	$59.9K
J0897	Injection, denosumab, 1 mg	3,180	$20	$57.2K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	1,640	$20	$39.2K
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	6,800	$1	$27.2K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	400	$60	$23.9K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	140	$90	$12.3K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	120	$90	$11.3K
96365	The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease.	170	$50	$7.9K
99204	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider…	30	$110	$3.9K

Showing 1–10 of 15

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 15 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. New Mexico Distribution

Jacqueline Dean — 0 of 15 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — New Mexico

Full comparison — all codes billed, vs. state median

15 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	4	10	9,930	$30	$358.6K
J0717	4	10	56,620	$1	$255.7K
J1602	5	10	8,900	$10	$132.4K
J0897	24	50	3,150	$20	$113.2K
J1745	4	10	1,690	$30	$44.5K
96413	30	40	170	$90	$17.7K
99214	1,095	2,700	90	$70	$12.9K
99213	183	2,440	60	$50	$7.3K
96365	12	40	80	$40	$6K
96367	24	20	140	$20	$4.9K

Showing 1–10 of 15

Related Providers

Other providers that share a Tax Identification Number (TIN) with Jacqueline Dean, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Scott Stoerner	NM	Rheumatology Physician	$1.5M	$0
Leroy Pacheco	NM	Rheumatology Physician	$787.7K	$0

Nearby Providers

Other providers in the same ZIP code as Jacqueline Dean, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Tricore Reference Laboratories	NM	Clinical Medical Laboratory	$0	$64.8M
Bright Horizons, Inc.	NM	Intellectual and/or Developmental Disabilities Residential Treatment Facility	$0	$46.9M
Lovelace Health System LLC	NM	General Acute Care Hospital	$0	$45.2M
Tricore Inc.	NM	Clinical Medical Laboratory	$7M	$35.8M
App Of New Mexico Ed PLLC	NM	Emergency Medicine Physician	$0	$42M
Duke City Recovery Toolbox LLC	NM	Community/Behavioral Health Agency	$108.4K	$28M
Metro Treatment Of New Mexico LP	NM	Methadone Clinic	$220.4K	$27.9M
Enchanted Care Solutions, LLC	NM	Home Health Agency	$0	$25.8M
Open Skies Healthcare	NM	Community/Behavioral Health Agency	$0	$23.8M
Krossroads Integrative Health And Recovery Solutions Inc	NM	Mental Health Clinic/Center (Including Community Mental Health Center)	$0	$16.7M

Jacqueline Dean — Billing Profile & Reimbursement Data

Sign up for Jacqueline Dean — Billing Profile & Reimbursement Data policy alerts

Jacqueline Dean — Billing Profile & Reimbursement Data

Sign up for Jacqueline Dean — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References